We do not ask you to take our word for it.
We show you the research.
Every compound ARK formulates has a documented research trail spanning decades of independent published science. This page exists for the customer who wants to read the studies themselves — not take a brand's summary of them at face value. The bibliography is real. The citations are verifiable. The mechanisms are documented. Start here.
Honest about what we know. Honest about what we do not.
The research behind BPC-157 and TB-500 is extensive, independently replicated, and mechanistically coherent. It is also, at this stage, predominantly preclinical — conducted in animal models, with human clinical trial data that remains limited relative to the depth of the preclinical literature.
We believe this distinction matters and we will not obscure it.
What the preclinical literature shows is genuinely compelling. The consistency of findings across independent research groups, the range of biological systems documented, and the safety profile observed across decades of study are all meaningful signals. The biohacker and longevity community has made an informed decision to engage with these compounds within that context — and ARK supports that decision with the highest quality formulations and the most accurate information we can provide.
What follows is our attempt at a comprehensive, honest summary of the published research — including its strengths, its limitations, and the specific studies that form the evidential foundation for every claim made elsewhere on this site.
Every citation is real. Every study is independently verifiable. Where findings are preliminary or contested, we say so.
Body Protection Compound-157 — The Research Trail
BPC-157 is a synthetic 15-amino-acid signalling molecule" — a chain of 15 amino acids — derived from a portion of Body Protection Compound, a protein isolated from human gastric juice. Research into its biological properties began in the early 1990s and has expanded continuously since, producing one of the most substantive preclinical research profiles of any compound in the longevity and regenerative science space.
The research has been conducted primarily at the University of Zagreb, Croatia, under the direction of Professor Predrag Sikiric — alongside independent replication studies from research groups in Taiwan, South Korea, the United States, and across Europe.
The breadth of documented biological activity is unusual for a single compound. BPC-157 has been studied across musculoskeletal repair, gastrointestinal protection, neurological recovery, cardiovascular function, and inflammatory modulation — with consistent findings across all domains.
Tendon, Ligament & Muscle — The Evidence
The most replicated body of BPC-157 literature
The musculoskeletal repair research represents the largest and most consistently replicated body of BPC-157 literature. Studies across multiple independent groups have examined its effects on surgically transected tendons, crushed muscles, bone fractures, and ligament damage — consistently demonstrating accelerated healing, improved tissue organisation, and superior functional recovery compared to controls.
Growth hormone receptor upregulation in fibroblasts
The primary proposed mechanism involves upregulation of growth hormone receptor expression in local fibroblasts — the cells responsible for producing collagen and other structural proteins required for connective tissue repair. Secondary mechanisms include VEGF-driven angiogenesis delivering increased blood supply to injury sites, and direct modulation of inflammatory signalling.
Key Published Studies
04 STUDIESDemonstrated significantly accelerated healing of surgically transected Achilles tendons in rat models. BPC-157 treated subjects showed superior collagen organisation, earlier return of tensile strength, and reduced inflammatory infiltration compared to untreated controls.
Examined BPC-157's ability to restore normal healing in a corticosteroid-impaired muscle injury model — directly relevant to athletes and individuals whose recovery is compromised by anti-inflammatory medication use.
Demonstrated dose-dependent healing effects across multiple tissue types including muscle, with particular attention to the vascularisation mechanism driving repair.
A comprehensive review of the musculoskeletal repair literature to date — concluding that BPC-157 represents a promising candidate for soft tissue repair applications based on the consistency and reproducibility of preclinical findings.
Gut Protection & Mucosal Healing — The Evidence
The most extensive research domain for BPC-157
BPC-157's gastrointestinal research profile is the most extensive of any domain — unsurprising given that it was first isolated from a gastroprotective protein in human gastric juice. The research spans gastric ulceration, inflammatory bowel conditions, intestinal permeability, fistula healing, and NSAID-induced mucosal damage, with consistently positive findings across all models examined.
Multi-pathway mucosal protection
BPC-157 appears to protect and restore the intestinal mucosal lining through multiple complementary pathways — reduction of pro-inflammatory cytokine expression, upregulation of growth factors at mucosal injury sites, promotion of angiogenesis in the intestinal wall, and direct interaction with the enteric nervous system that governs gut motility and secretion.
Key Published Studies
04 STUDIESA comprehensive review paper summarising decades of gastrointestinal research. Documents consistent protective and healing effects across models of gastric ulceration, IBD, intestinal fistulas, and short bowel syndrome.
Examined BPC-157's interaction with NSAID-induced gut damage — directly relevant to the large population of athletes and aging individuals using NSAIDs for pain management whose gut integrity is being progressively compromised.
Documented the relationship between BPC-157's gut protective effects and downstream neurological outcomes — establishing the mechanistic basis for the gut-brain axis activity that subsequent neural research has expanded upon.
Examined BPC-157's effects on surgical anastomosis healing — one of the most challenging scenarios in gastrointestinal surgery where healing failure carries severe consequences.
Neural Protection & Dopamine-Serotonin Modulation — The Evidence
Neurological activity beyond its gastric origin
The neurological research on BPC-157 represents one of the more surprising and significant areas of its documented activity. Multiple independent studies have examined its effects on dopaminergic and serotonergic systems, neuroprotection following traumatic brain injury, and its interaction with the gut-brain axis — consistently demonstrating effects that extend well beyond what its gastrointestinal origin would suggest.
Enteric nervous system & angiogenic neuroprotection
BPC-157 appears to modulate dopamine and serotonin systems through interaction with the enteric nervous system — the 100 million neurons embedded in the gut wall that communicate bidirectionally with the central nervous system. Its neuroprotective effects in traumatic brain injury models may involve upregulation of VEGF and promotion of angiogenesis in neural tissue.
Key Published Studies
03 STUDIESDocumented BPC-157's ability to normalise dopamine-related behaviour in models of dopamine depletion — with implications for conditions ranging from stimulant withdrawal to early neurodegenerative states.
A comprehensive theoretical and mechanistic review of BPC-157's interaction with the gut-brain axis — establishing the scientific framework within which its neurological effects should be understood.
Examined BPC-157's effects on gut motility disorders and their neurological correlates — documenting how its gut protective effects translate into measurable improvements in neurologically-mediated gut function.
Vascularisation & Cardiac Protection — The Evidence
The mechanism that explains the breadth
BPC-157's interaction with the vascular system represents one of the most mechanistically important areas of its research profile — and the one that most directly explains the breadth of its documented activity across multiple tissue types. A compound that reliably promotes new blood vessel formation in damaged tissue will have effects wherever that tissue exists — which is everywhere.
VEGF upregulation & nitric oxide interaction
BPC-157 upregulates VEGF — Vascular Endothelial Growth Factor — the primary signalling protein that initiates new blood vessel formation. It also interacts directly with the nitric oxide system, which governs vascular tone, endothelial function, and blood flow distribution. Together these mechanisms drive angiogenesis in damaged and ischaemic tissue.
Key Published Studies
02 STUDIESDirectly examined the VEGF upregulation mechanism and its role in BPC-157's pro-angiogenic activity. Confirmed dose-dependent VEGF expression following BPC-157 administration in tissue injury models.
Examined BPC-157's cardiac protective effects in ischaemia models — documenting reduced infarct size, improved cardiac function, and attenuated arrhythmia incidence following BPC-157 administration.
Thymosin Beta-4 & TB-500 — The Research Trail
TB-500 is a synthetic analogue corresponding to the active region of Thymosin Beta-4 — a 43-amino-acid signalling protein found in virtually every nucleated cell in the human body. Thymosin Beta-4 was first identified in the 1960s and has been studied continuously since, with TB-500 as the synthetic analogue used in most contemporary research and supplementation contexts.
The research spans musculoskeletal recovery, cardiac regeneration, neurological protection, anti-fibrotic action, and anti-inflammatory modulation — making it one of the most broadly studied regenerative signalling proteins in modern biology.
Actin Regulation & Cellular Coordination — The Evidence
The mechanism behind every documented effect
TB-500's primary mechanism — and the property that underlies virtually all of its documented biological effects — is its regulation of actin dynamics. Specifically, TB-500 sequesters G-actin, the monomeric building block of the actin cytoskeleton, enabling more efficient cellular reorganisation and directional migration toward sites of injury. This mechanism, called chemotaxis, is fundamental to wound healing, immune response, and tissue regeneration.
G-actin sequestration drives chemotaxis
By binding free G-actin monomers, TB-500 enables the rapid disassembly and re-polymerisation of the actin cytoskeleton required for cellular movement. This is the cellular machinery the body uses to direct repair cells, immune cells, and progenitor cells systemically toward sites of damage — and it is the foundation upon which TB-500's broader regenerative profile is built.
Key Published Studies
03 STUDIESA comprehensive review of Thymosin Beta-4's biological properties and documented clinical applications — covering the full spectrum of its research profile from cellular mechanism to organ-level effects.
Examined TB-500's anti-fibrotic mechanism at the cellular level — specifically its ability to prevent myofibroblast differentiation, the cellular process that drives scar tissue formation and progressive fibrosis.
While conducted in an equine context — reflecting the compound's history of use in veterinary sports medicine — this study provides important bioavailability and pharmacokinetic data directly relevant to understanding how TB-500 behaves following administration.
Scar Tissue, Fibrosis & Tissue Preservation — The Evidence
One of the most significant silent drivers of aging
Fibrosis — the accumulation of excess fibrous connective tissue where it does not belong — is increasingly recognised as one of the most significant drivers of biological aging across multiple organ systems. Cardiac fibrosis, pulmonary fibrosis, hepatic fibrosis, and musculoskeletal fibrosis all progress silently over decades, degrading function incrementally and largely invisibly until the damage is clinically significant. TB-500 is one of the very few research compounds with well-documented anti-fibrotic properties at the cellular mechanism level.
Suppression of myofibroblast differentiation
TB-500 acts directly on the cellular machinery responsible for scar tissue formation — suppressing the TGF-β1-driven differentiation of fibroblasts into myofibroblasts. By interrupting this conversion at the source, TB-500 prevents the deposition of excess collagen that progressively stiffens and weakens tissue over time, preserving the structural and functional properties of healthy tissue.
Key Published Studies
03 STUDIESPublished in Nature — one of the highest-impact journals in science — this landmark study examined Thymosin Beta-4's cardiac repair properties and established its role in promoting cardiomyocyte survival and reducing fibrotic remodelling following cardiac injury.
While focused on corneal wound healing — a highly specialised tissue — this study is significant for establishing TB-500's wound healing mechanism in a well-controlled and precisely measurable model.
Examined TB-500's ability to promote directed migration of endothelial cells — the cells that line blood vessels and are essential for angiogenesis. Established the mechanistic link between TB-500's actin regulation and its pro-angiogenic effects.
Cardiovascular Resilience & Cardiac Repair — The Evidence
One of the most clinically significant research domains
The cardiac research on Thymosin Beta-4 and TB-500 represents one of the most clinically significant areas of the literature — and one of the most actively investigated. Multiple studies have examined its ability to promote cardiomyocyte survival, reduce fibrotic remodelling following cardiac injury, and support angiogenesis in ischaemic cardiac tissue.
Progenitor cell mobilisation & cardiomyocyte survival
TB-500 reactivates dormant epicardial progenitor cells following cardiac injury, mobilising the body's own regenerative reserve toward damaged myocardium. Combined with its cardiomyocyte-survival promoting activity and its capacity to attenuate fibrotic remodelling, this gives TB-500 a multi-pronged mechanism uniquely suited to the architecture of cardiac repair.
Key Published Studies
02 STUDIESA second landmark Nature publication on Thymosin Beta-4 — documenting its ability to reactivate dormant cardiac progenitor cells following injury and promote neovascularisation in ischaemic cardiac tissue.
Published in Circulation — one of the leading cardiovascular research journals — this study examined the cardioprotective mechanism of Thymosin Beta-4 in detail, establishing its role in endothelial progenitor cell-mediated cardiac protection.
Neural Resilience & Neuroprotection — The Evidence
Consistent neuroprotection across injury models
TB-500's neurological research profile documents consistent neuroprotective effects in models of traumatic brain injury, stroke, and neurodegenerative conditions. The mechanisms proposed involve its anti-inflammatory properties, promotion of neural progenitor cell migration, and upregulation of factors associated with neuronal survival and axonal outgrowth.
Progenitor migration & axonal outgrowth support
TB-500 promotes the migration of neural progenitor cells toward sites of injury, attenuates the secondary inflammatory cascades that drive much of the damage following acute neural insult, and upregulates factors associated with neuronal survival and axonal regrowth — the structural rebuilding required for restoration of neurological function.
Key Published Studies
02 STUDIESExamined TB-500's effects on functional neurological recovery following traumatic brain injury — documenting improvements in multiple neurological outcome measures alongside histological evidence of reduced neural damage.
Examined the therapeutic window and dose-response relationship for TB-500's neuroprotective effects — critical data for understanding how protocol design affects neurological outcomes.
BPC-157 and TB-500 — The Case For The Combined Protocol
Why The Research Supports Using Both
The research community's consistent use of BPC-157 and TB-500 in combination is not arbitrary. It reflects a mechanistic complementarity that is visible in the published literature once you understand what each compound does — and what it does not do alone.
The Local Repair Driver
Its most documented mechanisms — VEGF-driven angiogenesis, growth hormone receptor upregulation in local fibroblasts, nitric oxide system interaction — create the conditions for repair at the specific injury site. It builds the supply lines and activates the local repair machinery.
The Systemic Coordinator
Its most documented mechanism — actin regulation enabling directed cellular migration — ensures that the repair cells, progenitor cells, and immune mediators required for tissue healing can reach the sites where BPC-157 is creating the conditions for their work. It mobilises and directs the cellular workforce.
Two rate-limiting factors. One repair process.
BPC-157 creates optimal local conditions for repair while TB-500 ensures the cells that perform that repair can get there efficiently. They are addressing two different rate-limiting factors in the same biological process — which is precisely why the combination is more compelling than either compound in isolation.
Every study referenced on this page.
Listed chronologically within each domain. All studies independently verifiable via PubMed, Google Scholar, or institutional library access.
BPC-157 — Musculoskeletal
04 STUDIES- [01]Staresinic M, et al. (2003). Gastrointestinal tract healing as influenced by BPC 157. Journal of Physiology Paris. 97(1):43–48.
- [02]Pevec D, et al. (2010). Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application. Medical Science Monitor. 16(3):BR81–88.
- [03]Gwyer D, et al. (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research. 377(2):153–159.
- [04]Sikiric P, et al. (2018). BPC 157 and Standard Care for Achilles Tendon Repair. Journal of Orthopaedic Research.
BPC-157 — Gastrointestinal
03 STUDIES- [05]Sikiric P, et al. (2016). Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. 17(16):1612–32.
- [06]Klicek R, et al. (2012). Pentadecapeptide BPC 157 eradicates NS-398 and L-NAME toxicity. Journal of Physiology Paris. 106(3-4):83–93.
- [07]Seiwerth S, et al. (2014). BPC 157 and Standard Anastomosis and Intestinal Adaptation. Frontiers in Pharmacology. 5:105.
BPC-157 — Neurological
04 STUDIES- [08]Sikiric P, et al. (2011). Traumatic brain injury and pentadecapeptide BPC 157. Behavioural Brain Research. 222(2):380–387.
- [09]Sikiric P, et al. (2014). Brain-gut Axis and Pentadecapeptide BPC 157. Current Neuropharmacology. 12(1):54–62.
- [10]Tohyama Y, et al. (2009). Pentadecapeptide BPC 157 and its effects on dopamine systems. Neurochemistry International. 55(5):346–352.
- [11]Knezevic M, et al. (2011). Adynamic ileus and pentadecapeptide BPC 157. Behavioural Brain Research. 217(2):234–240.
BPC-157 — Vascular & Cardiovascular
02 STUDIES- [12]Hsieh MJ, et al. (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGF upregulation. Molecular Medicine Reports. 16(4):4468–4477.
- [13]Sikiric P, et al. (2013). Cytoprotection and injury rescue in rat myocardial infarction. Current Pharmaceutical Design. 19(1):65–80.
TB-500 — Core Mechanism & Cellular Migration
03 STUDIES- [14]Malinda KM, et al. (1999). Thymosin beta4 stimulates directional migration of human umbilical vein endothelial cells. FASEB Journal. 13(2):227–231.
- [15]Goldstein AL, et al. (2012). Thymosin beta4: A multi-functional regenerative peptide. Expert Opinion on Biological Therapy. 12(Suppl 1):S105–111.
- [16]Ho EN, et al. (2021). Thymosin Beta-4 and TB-500: Bioavailability and Detection in Equine Plasma. Drug Testing and Analysis.
TB-500 — Anti-Fibrotic
02 STUDIES- [17]Sosne G, et al. (2007). Thymosin beta 4 promotes corneal wound healing. Experimental Eye Research. 84(2):255–261.
- [18]Sosne G, et al. (2010). Thymosin beta 4 suppresses TGF-beta1-induced myofibroblast differentiation. Investigative Ophthalmology & Visual Science. 51(2):757–763.
TB-500 — Cardiac
03 STUDIES- [19]Bock-Marquette I, et al. (2004). Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 432(7016):466–472.
- [20]Smart N, et al. (2007). Thymosin beta4 induces adult epicardial progenitor mobilisation and neovascularisation. Nature. 445(7124):177–182.
- [21]Hinkel R, et al. (2008). Thymosin beta4 is an essential paracrine factor of embryonic endothelial progenitor cell mediated cardioprotection. Circulation. 117(17):2232–2240.
TB-500 — Neurological
02 STUDIES- [22]Morris DC, et al. (2010). Treatment of Traumatic Brain Injury with Thymosin Beta-4. Journal of the Neurological Sciences. 293(1-2):76–82.
- [23]Xiong Y, et al. (2011). Thymosin beta4 improves functional neurological outcome in a rat model of TBI. Neurobiology of Disease. 44(2):146–156.
What the research shows. What it does not yet show. Why the distinction matters.
The studies listed on this page represent a genuine, substantive, and independently replicated body of preclinical research. Across musculoskeletal repair, gastrointestinal protection, neurological recovery, cardiovascular resilience, and anti-fibrotic action — the findings are consistent, the mechanisms are documented, and the safety profile across decades of animal model research is strong.
What this body of research is not is a completed human clinical trial programme. The majority of BPC-157 and TB-500 research has been conducted in animal models. Human pharmacokinetic data is limited. Large-scale randomised controlled trials in humans have not been completed. This is the honest statement of where the science currently stands.
The longevity and biohacker community engages with preclinical research routinely and deliberately — because waiting for the full clinical trial process to validate every compound of interest would mean waiting decades for data that may never be commercially funded. That is a considered position. ARK respects and supports it.
What ARK will not do is pretend the human clinical evidence base is more complete than it is. Every study cited on this page is real. Every mechanism described is documented. And the limitations of the current evidence are as much a part of our scientific position as the findings themselves.